The Motley Fool Australia
9-21
Telix to buy ITM for US$1.65 billion upfront, with up to US$700 million in milestones
Telix Pharmaceuticals said it will acquire 100% of ITM for US$1.65 billion upfront, with up to US$700 million in milestone payments. ITM reported US$273 million in 2025 revenue and a 40% CAGR from 2021–2025. On a pro forma basis, the combined group is projected to generate more than US$1.3 billion in 2026 revenue, with Telix shareholders expected to own about 76.3% after completion. The deal remains subject to shareholder and regulatory approvals, with closing expected by the end of FY2026.